menu
    • menu

    Company profile for Kelonia Therapeutics

    NEW Drugs in Dev.: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for soli...
    Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal of bringing genetic medicines to every patient in need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kelonia TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Boston, Massachusetts
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://keloniatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kelonia-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kelonia Therapeutics Unveils Phase 1 Data On KLN-1010 BCMA CAR-T
    Kelonia Therapeutics Unveils Phase 1 Data On KLN-1010 BCMA CAR-T

    09 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-09/kelonia-therapeutics-presents-first-in-human-data-from-phase-1-inmmycar-study-of-kln-1010-in-vivo-bc

    PHARMIWEB
    09 Dec 2025
    Share Share
    Kelonia Therapeutics Presents First-In-Human BCMA CAR-T Data
    Kelonia Therapeutics Presents First-In-Human BCMA CAR-T Data

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124182363/en/Kelonia-Therapeutics-Announces-Late-Breaking-Oral-Presentation-of-First-in-Human-Data-from-in-vivo-BCMA-CAR-T-Therapy-at-the-American-Society-of-Hematology-ASH-2025-Annual-Meeting

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Kelonia Doses First Patient In Ph 1 inMMyCAR For Multiple Myeloma
    Kelonia Doses First Patient In Ph 1 inMMyCAR For Multiple Myeloma

    19 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250819154555/en/Kelonia-Therapeutics-Doses-First-Patient-in-Phase-1-inMMyCAR-Study-Evaluating-in-vivo-CAR-T-Cell-Therapy-for-Relapsed-and-Refractory-Multiple-Myeloma

    BUSINESSWIRE
    19 Aug 2025
    Share Share
    Kelonia Therapeutics to Present iGPS® Data at ASGCT 2025 Meeting
    Kelonia Therapeutics to Present iGPS® Data at ASGCT 2025 Meeting

    09 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250509454554/en/Kelonia-Therapeutics-to-Present-iGPS-Preclinical-Data-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2025-Annual-Meeting

    BUSINESSWIRE
    09 May 2025
    Share Share
    Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
    Kelonia Therapeutics to Participate in Upcoming Scientific Conferences

    02 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240502664313/en

    BUSINESSWIRE
    02 May 2024
    Share Share
    Kelonia to Present Preclinical Data Highlighting Therapeutic Potential
    Kelonia to Present Preclinical Data Highlighting Therapeutic Potential

    02 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240402710975/en

    BUSINESSWIRE
    02 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search